Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA™ Abuse Deterrent Transdermal Technology Patent
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Present
Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24
Nutriband with Kindeva Drug Delivery demonstrate enhanced abuse-deterrent characteristics for Aversa™ Fentanyl